Recommendations for biomarker identification and qualification in clinical proteomics

Science Translational Medicine

Volumn 2, Issue 46, 2010, Pages

  Mischak, Harald ^a   Allmaier, Günter ^a   Apweiler, Rolf ^a   Attwood, Teresa ^a   Baumann, Marc ^a   Benigni, Ariela ^a   Bennett, Samuel E ^a   Bischoff, Rainer ^a   Bongcam Rudloff, Erik ^a   Capasso, Giovambattista ^a   Coon, Joshua J ^a   D'Haese, Patrick ^a   Dominiczak, Anna F ^a   Dakna, Mohammed ^a   Dihazi, Hassan ^a   Ehrich, Jochen H ^a   Fernandez Llama, Patricia ^a   Fliser, Danilo ^a   Frokiaer, Jorgen ^a   Garin, Jerome ^a   Girolami, Mark ^a   Hancock, William S ^a   Haubitz, Marion ^a   Hochstrasser, Denis ^a   Holman, Rury R ^a   Ioannidis, John P A ^a   Jankowski, Joachim ^a   Julian, Bruce A ^a   Klein, Jon B ^a   Kolch, Walter ^a   Luider, Theo ^a   Massy, Ziad ^a   Mattes, William B ^a   Molina, Franck ^a   Monsarrat, Bernard ^a   Novak, Jan ^a   Peter, Karlheinz ^a   Rossing, Peter ^a   Sánchez Carbayo, Marta ^a   Schanstra, Joost P ^a   Semmes, O John ^a   Spasovski, Goce ^a   Theodorescu, Dan ^a   Thongboonkerd, Visith ^a   Vanholder, Raymond ^a   Veenstra, Timothy D ^a   Weissinger, Eva ^a   Yamamoto, Tadashi ^a   Vlahou, Antonia ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; CALIBRATION; CHEMICAL COMPOSITION; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE MARKER; MACHINE LEARNING; MASS SPECTROMETRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SAMPLE SIZE; SAMPLING; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STATISTICAL ANALYSIS; VALIDATION PROCESS; ARTICLE; HUMAN;

BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 77956112961     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001249     Document Type: Review

References (41)

1. S. Decramer, S. Wittke, H. Mischak, P. Zürbig, M. Walden, F. Bouissou, J. L. Bascands, J. P. Schanstra, Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 12, 398-400 (2006).
2. E. M. Weissinger, E. Schiffer, B. Hertenstein, J. L. Ferrara, E. Holler, M. Stadler, H. J. Kolb, A. Zander, P. Zürbig, M. Kellmann, A. Ganser, Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109, 5511-5519 (2007).
3. K. Rossing, H. Mischak, M. Dakna, P. Zürbig, J. Novak, B. A. Julian, D. M. Good, J. J. Coon, L. Tarnow, P. Rossing; PREDICTIONS Network, Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 19, 1283-1290 (2008).
4. http://www.controlled-trials.com/ISRCTN03911524/ISRCTN03911524.
5. N. Rifai, M. A. Gillette, S. A. Carr, Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983 (2006).
6. A. Alaiya, M. Al-Mohanna, S. Linder, Clinical cancer proteomics: Promises and pitfalls. J. Proteome Res. 4, 1213-1222 (2005).
7. E. F. Petricoin, III, A. M. Ardekani, B. A. Hitt, P. J. Levine, V. A. Fusaro, S. M. Steinberg, G. B. Mills, C. Simone, D. A. Fishman, E. C. Kohn, L. A. Liotta, Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
8. D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, D. E. Malehorn, G. Malik, D. Oelschlager, A. Partin, T. Randolph, N. Rosenzweig, S. Srivastava, S. Srivastava, I. M. Thompson, M. Thornquist, D. Troyer, Y. Yasui, Z. Zhang, L. Zhu, O. J. Semmes, Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias. Clin. Chem. 54, 44-52 (2008).
9. J. Hu, K. R. Coombes, J. S. Morris, K. A. Baggerly, The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales. Brief. Funct. Genomics Proteomics 3, 322-331 (2005).
10. H. Mischak, R. Apweiler, R. E. Banks, M. Conaway, J. J. Coon, A. Dominizak, J. H. Ehrich, D. Fliser, M. Girolami, H. Hermjakob, D. F. Hochstrasser, V. Jankowski, B. A. Julian, W. Kolch, Z. Massy, C. Neususs, J. Novak, K. Peter, K. Rossing, J. P. Schanstra, O. J. Semmes, D. Theodorescu, V. Thongboonkerd, E. M. Weissinger, J. E. Van Eyk, T. Yamamoto, Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 1, 148-156 (2007).
11. M. A. Knepper, Common sense approaches to urinary biomarker study design. J. Am. Soc. Nephrol. 20, 1175-1178 (2009).
12. http://www3.interscience.wiley.com/homepages/112770559/2456-instruc.pdf.
13. http://www.mcponline.org/cpmeeting/cguidelines.pdf.
14. J. P. Ioannidis, Why most published research findings are false. PLoS Med. 2, e124 (2005).
15. A. Vlahou, G. Allmaier, T. Attwood, E. Bongcam-Rudloff, A. Charonis, J. Frokiaer, H. Mischak, J. Schanstra, G. Spasovski, 2nd combined working group and management committee meeting of urine and kidney proteomics COST action 29-30 March 2009, Nafplio, Greece. Proteomics Clin. Appl. 3, 1017-1022 (2009).
16. A. Brazma, P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. Aach, W. Ansorge, C. A. Ball, H. C. Causton, T. Gaasterland, P. Glenisson, F. C. Holstege, I. F. Kim, V. Markowitz, J. C. Matese, H. Parkinson, A. Robinson, U. Sarkans, S. Schulze-Kremer, J. Stewart, R. Taylor, J. Vilo, M. Vingron, Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
17. D. Moher, S. Hopewell, K. F. Schulz, V. Montori, P. C. Gøtzsche, P. J. Devereaux, D. Elbourne, M. Egger, D. G. Altman, CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 340, (mar23 1), c869 (2010).
18. E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, J. P. Vandenbroucke; STROBE Initiative, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 335, 806-808 (2007).
19. P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, J. G. Lijmer, D. Moher, D. Rennie, H. C. de Vet; Standards for Reporting of Diagnostic Accuracy, Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. BMJ 326, 41-44 (2003).
20. J. A. Wagner, Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48, 631-651 (2008).
21. C. A. Altar, D. Amakye, D. Bounos, J. Bloom, G. Clack, R. Dean, V. Devanarayan, D. Fu, S. Furlong, L. Hinman, C. Girman, C. Lathia, L. Lesko, S. Madani, J. Mayne, J. Meyer, D. Raunig, P. Sager, S. A. Williams, P. Wong, K. Zerba, A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin. Pharmacol. Ther. 83, 368-371 (2008).
22. H. Mischak, P. Rossing, Proteomic biomarkers in diabetic nephropathy - Reality or future promise? Nephrol. Dial. Transplant. 22, (2010).
23. F. Goodsaid, J. E. Bandow, H. Mischak, Grand rounds in proteomics at the FDA White Oak, Silver Spring, MD, USA, April 3, 2007. Proteomics Clin. Appl. 1, 1526-1531 (2007).
24. J. W. Lee, V. Devanarayan, Y. C. Barrett, R. Weiner, J. Allinson, S. Fountain, S. Keller, I. Weinryb, M. Green, L. Duan, J. A. Rogers, R. Millham, P. J. O'Brien, J. Sailstad, M. Khan, C. Ray, J. A. Wagner, Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312-328 (2006).
25. M. Buzoianu, J. B. Kadane, Adjusting for verification bias in diagnostic test evaluation: A Bayesian approach. Stat. Med. 27, 2453-2473 (2008).
26. J. H. Page, A. Rotnitzky, Estimation of the disease-specific diagnostic marker distribution under verification bias. Comput. Stat. Data Anal. 53, 707-717 (2009).
27. S. Decramer, A. Gonzalez de Peredo, B. Breuil, H. Mischak, B. Monsarrat, J.-L. Bascands, J. P. Schanstra, Urine in clinical proteomics. Mol. Cell. Proteomics 7, 1850-1862 (2008).
28. D. M. Good, V. Thongboonkerd, J. Novak, J. L. Bascands, J. P. Schanstra, J. J. Coon, A. Dominiczak, H. Mischak, Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the future. J. Proteome Res. 6, 4549-4555 (2007).
29. www.labcompliance.com/info/links/methods/guidelines.aspx.
30. R. V. Hogg, E. A. Tanis, Probability and Statistical Interference (McMillian, New York, 2009).
31. S. Dudoit, M. J. van der Laan, Multiple Testing Procedures with Applications to Genomics (Springer, New York, 2008).
32. D. I. Broadhurst, D. B. Kell, Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2, 171-196 (2006).
33. H. Mischak, J. J. Coon, J. Novak, E. M. Weissinger, J. P. Schanstra, A. F. Dominiczak, Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom. Rev. 28, 703-724 (2009).
34. A. Statnikov, C. F. Aliferis, I. Tsamardinos, D. Hardin, S. Levy, A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics 21, 631-643 (2005).
35. S. Dudoit, J. Fridlyand, T. P. Speed, Comparison of discrimination methods for the classification of tumors using gene expression data. J. Am. Stat. Assoc. 97, 77-87 (2002).
36. M. Haubitz, D. M. Good, A. Woywodt, H. Haller, H. Rupprecht, D. Theodorescu, M. Dakna, J. J. Coon, H. Mischak, Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol. Cell. Proteomics 8, 2296-2307 (2009).
37. J. P. Ioannidis, Why most discovered true associations are inflated. Epidemiology 19, 640-648 (2008).
38. U. M. Braga-Neto, E. R. Dougherty, Is cross-validation valid for small-sample microarray classification? Bioinformatics 20, 374-380 (2004).
39. http://www.bbmri.eu/.
40. http://www.eurokup.org/node/132.
41. Funding: This initiative was supported in part by the EuroKUP COST-Action (BM0702; www.eurokup.org), by the European Community's 6th Framework Programme, grant agreement LSHM-CT-2006-037093 (InGenious Hyper-Care), and by the European Community's 7th Framework Programme, grant agreement HEALTH-F2-2009-241544 (SysKID). A.F.D. wishes to acknowledge support of the British Heart Foundation Chair and Programme Grants (BHF RG/07/005/23633). B.A.J. and J.N. acknowledge their support in part from NIH grants DK075868, DK078244, DK082753, DK083663, and DK080301. B.M. and J.P.S. acknowledge the support from the Agence Nationale pour la Recherche (ANR-07-PHYSI O-004-01), the Fondation pour la Recherche Médicale "Grands Equipements pour la Recherche Biomédicale, " and the CPER2007-2013 program. J.J. was supported by a grant from Federal Ministry of Education and Research (01GR0807). W.H. acknowledges support by NCI grant CA 128427 and Korean WCU grant R31-2008-000-10086-0. A.V. and J.G. acknowledge support from FP7 DECanBio (grant agreement 201333). O.J.S. acknowledges support from NIH/NCI CA CA085067. Competing interests: H.M. is the co-founder and co-owner of Mosaiques-Diagnostics. W.B.M. is the founder and principal of PharmPoint Consulting. The other authors declare that they have no competing interests.